Multiple Biomarkers to Predict Major Adverse Cardiovascular Events in Patients With Coronary Chronic Total Occlusions ===================================================================================================================== * Srikanth Adusumalli * Reza Mohebi * Cian P. McCarthy * Craig A. Megaret * Rhonda F. Rhyne * Farouc A. Jaffer * James L. Januzzi ## Abstract **Background** There are limited tools available to predict the long-term prognosis of persons with coronary chronic total occlusions (CTO). **Objectives** We evaluated performance of a blood biomarker panel to predict cardiovascular (CV) events in patients with CTO. **Methods** From 1251 patients in the CASABLANCA study, 241 participants with a CTO were followed for an average of 4 years for occurrence of major adverse CV events (MACE, CV death, non-fatal myocardial infarction or stroke) and CV death/heart failure (HF) hospitalization. Results of a biomarker panel (kidney injury molecule-1, N-terminal pro-B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1) from baseline samples were expressed as low-, moderate-, and high-risk. **Results** By 4 years, a total of 67 (27.8%) MACE events and 56 (23.2%) CV death/HF hospitalization events occurred. The C-statistic of the panel for MACE through 4 years was 0.79. Considering patients in the low-risk group as a reference, the hazard ratio of MACE by 4 years was 6.65 (95% confidence interval [CI]: 2.98-14.8) and 12.4 (95% CI:5.17-29.6) for the moderate and high-risk groups (both P <0.001). The C-statistic for CVD/HF hospitalization by 4 years was 0.84. Compared to the low-risk score group, the moderate and high-risk groups had hazard ratios of 5.61 (95% CI: 2.33-13.5) and 15.6 (95% CI: 6.18, 39.2; both P value <0.001). **Conclusion** A multiple biomarker panel assists in evaluating the risk of adverse outcomes in patients with coronary CTO. These results may have implications for patient care and could have a role for clinical trial enrichment. **Clinical Trial** CASABLANCA, [ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: [NCT00842868](http://medrxiv.org/lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00842868&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) Keywords * chronic total occlusion * percutaneous coronary intervention * prognosis * coronary artery disease * biomarker Approximately 1 in 4 patients with obstructive coronary artery disease on coronary angiography have a chronic total occlusion (CTO)1, defined as 100 percent stenosis of a coronary artery with Thrombolysis In Myocardial Infarction (TIMI) 0 flow for a duration of at least three months2. These common coronary lesions are associated with a worse overall prognosis, with higher rates of major adverse cardiovascular events (MACE)3–5. While the symptomatic and prognostic benefit of CTO percutaneous coronary intervention (PCI) is supported by observational studies and registries6–9, randomized controlled trial evidence is conflicting regarding the role of CTO PCI in improving patient outcomes10–15. Therefore, new approaches to stratify the risk of CTO patients could provide clinical value and inform future randomized trials studying CTO PCI for prognostic benefit. Despite its potential benefits, CTO PCI has a potentially substantial risk for peri-procedural complications including the risk of coronary artery perforation6, 16. Presently the primary indication for CTO PCI is limiting ischemic symptoms, despite prescribed optimal medical treatment. Rather than relying on such subjective assessment, objective measures to stratify risk among individuals with CTO would be useful to further support clinical decision-making. Surprisingly, minimal data is available regarding accurate risk stratification models to predict long-term clinical outcomes and prognosis in CTO patients. An accurate means for risk stratification could aid clinicians in making informed decisions about intensified/personalized medical therapy and inform risk/benefit ratio of CTO revascularization, including CTO PCI. In the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) study of individuals undergoing coronary angiography we previously described a multi-biomarker panel developed using targeted proteomics and machine learning (HART CVE; Prevencio, Inc, Kirkland WA). This panel, consisting of a weighted algorithm incorporating results from N-terminal pro-B type natriuretic peptide (NT-proBNP), kidney injury molecule-1 (KIM-1), osteopontin, and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) was highly accurate for predicting incident triple MACE, including non-fatal myocardial infarction (MI), non-fatal stroke, and cardiovascular (CV) death17. In the present analysis, we evaluated the performance of this biomarker panel in study participants with one or more CTO. We hypothesized that these novel biomarkers would allow us to risk-stratify patients with CTOs for incident triple MACE. Additionally, as individuals with CTOs often have symptoms of dyspnea and suffer heart failure (HF) events18 we also examined the ability of the biomarker panel to predict incident CV death or heart failure (HF) hospitalization. ## Methods All study procedures were approved by the MassGeneral/Brigham HealthCare Institutional Review Board and conducted in accordance with the Declaration of Helsinki. The design of the CASABLANCA study has been described previously17. Briefly, a sample of 1,251 patients undergoing coronary and/or peripheral angiography with or without intervention were prospectively enrolled at the Massachusetts General Hospital in Boston, Massachusetts between 2008 and 2011. Patients were referred for these procedures for numerous reasons, including angiography after acute myocardial infarction (MI), unstable angina pectoris, and HF, as well as for nonacute indications, such as stable chest pain and abnormal stress testing or pre-operatively before heart valve surgery. After obtaining informed consent, detailed clinical and historical variables and reasons for angiography were recorded at the time of the procedure. Results of coronary angiography (based on visual estimation at the time of the procedure) were recorded; the left main, left anterior descending, left circumflex, and right coronary artery were each considered major coronary arteries, and the highest percent stenosis within each major coronary artery or their branches was recorded. Detailed follow up was then undertaken for cardiovascular (CV), cerebrovascular and renal events and adjudicated using charter definitions. Outcomes assessed for an average of 3.7 years (maximum 8 years) included triple MACE (CV death/non-fatal MI/non-fatal stroke) and CV death/HF hospitalization. For the purposes of this analysis, all angiograms of study participants with 100% occlusions of a coronary vessel from their case report form were reviewed by the study author (SA). Those with CTO vessels (n=309) were further categorized CTOs into single-vessel, double-vessel, and triple-vessel CTOs. Presence of patent coronary bypass grafts to the CTO was determined. Those with a CTO but with a supplying patent graft (n=68) were excluded from the present analysis, leaving 241 individuals with at least 1 CTO for study analysis (**Figure 1**). ![Figure 1:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/07/23/2023.07.19.23292911/F1.medium.gif) [Figure 1:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/F1) Figure 1: Study flow chart of patients with ≥1 chronic total occlusion (CTO) vessel, excluding those with a patent graft supplying the CTO vessel. ### HART CVE Panel 15 mL of blood was obtained immediately pre- and post-catheterization, processed and frozen at -80 degrees Celsius. Blood was collected into chilled tubes, transported on ice, and centrifuged immediately. Following centrifugation, samples were aliquoted into freezer tubes and frozen immediately at -80 degrees. Analyses are typically performed on aliquots that have not been thawed. In this study, Luminex xMAP technology platform (Luminex Corporation, Austin, Texas) was used to measure concentrations of the 109 proteins listed in **Supplemental Table 1**. The Luminex approach uses multiplexed, microsphere-based assays in a single reaction vessel and is accomplished by assigning each protein-specific assay a recognizable microsphere-based fluorescence signature. The HART CVE panel (Prevencio, Kirkland WA) was previously developed using an artificial intelligence-leveraged algorithm19. After evaluating 109 candidate proteins, a panel of 4 biomarkers (NT-proBNP, KIM-1, osteopontin, and TIMP-1) was derived and used to train a mathematical algorithm, which comprises the HART CVE test panel. This panel results in a continuous result, that is divided into three categories corresponding to low-, medium-, and high-risk levels for CVE. Accordingly, in this analysis study participants were customarily classified into one of those three risk levels. ### Statistical analysis The distributions of variables were presented using mean (standard deviation), median (interquartile ranges), and count (frequency) as appropriate. Statistical significance of the variables was determined with the chi-square test for trend in proportions (for binary variables) or Spearman’s correlation coefficient test (for continuous variables). Cox proportional hazard regression was used to calculate the hazard ratio (95% confidence interval) of CVE risk levels for MACE and CV death/HF hospitalization outcomes. The primary analysis of interest was ability of the panel to predict each outcome by 4 years, however outcomes at 1 year, 2 years, and 4 years were all scrutinized. Cox proportional hazard regression assumptions were met using Schoenfeld residual test. Model discrimination and calibration were evaluated with Harrell’s c-statistic and Hosmer-Lemeshow test along with Aikake Information and Bayesian Information Criteria respectively. Statistical significance is defined as a 2-sided P value <0.05. All statistical analyses were performed using the R version 4.3.0 (R Foundation for Statistical Computing, Vienna, Austria. URL: [https://www.R-project.org/](https://www.R-project.org/)). ## Results From the CASABLANCA study, 241 study participants with at least 1 CTO (and without patent bypass graft sources of distal perfusion) were evaluated using the HART CVE panel. Baseline characteristics of study subjects were divided into three groups as low-, medium- and high-risk as detailed in **Table 1**. Medical comorbidities were similar among all risk groups except patients in higher risk group had higher prevalence of pre-existing HF. The median concentrations of KIM-1, NT-proBNP, osteopontin, and TIMP-1 were significantly higher in the high-risk group, as compared to the low and median risk groups. View this table: [Table 1:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/T1) Table 1: Baseline characteristics as a function of HART CVE Score. ### Distribution of CVE panel by the extent of CTOs The coronary risk status of participants was then considered as a function of their HART CVE result, expressed as low-, medium-, or high-risk. As displayed in **Table 2**, study participants with a high-risk HART CVE result had a greater number of vessels with >70% vessel stenosis compared to those with a low-risk result (Mean number of vessels: 1.57 vs. 1.13, p-value: 0.02), while the distribution of 1-, 2-, or 3-vessel CTO was comparable across HART CVE groupings. View this table: [Table 2:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/T2) Table 2: Distribution of CVE Panel by the extent of CTO. ### Performance of HART CVE Panel for triple MACE and CV death/HF hospitalization There were 40 (16.5%), 51 (21.1%) and 67 (27.8%) MACE events at 1, 2 and 4-year follow up respectively and 35 (14.5%), 42 (17.4%), 56 (23.2%) CV death/ HF hospitalisation events at 1, 2 & 4 years follow up respectively. The C-statistic of the model for predicting 4-year triple MACE was 0.79 (0.72, 0.85). As shown in **Table 3**, compared to the referent low-risk group, by one year, those with a moderate-risk HART CVE result had a hazard ratio (HR) with 95% confidence interval (CI) for MACE at 1 year of 5.32 (95% CI: 1.98, 14.3; P <0.001), while a high-risk HART CVE result had an associated HR of 14.7 (95% CI: 5.28, 40.8; P <0.001). Similar graded results for triple MACE were seen associated with moderate- and high-risk CVE scores at 2 years (moderate score HR: 5.46, 95% CI 1.84, 8.77; high score HR:14.1, 95% CI: 5.59, 35.5; both P <0.001) and at the 4-year time point (moderate score HR 6.65, 95% CI 2.98, 14.8; high score HR: 12.4, 95% CI: 5.17, 29.6; both P <0.001). The model was well-calibrated **(Table 4).** View this table: [Table 3:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/T3) Table 3: Performance of HART CVE panel for triple MACE across study time points. View this table: [Table 4:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/T4) Table 4: Calibration for triple MACE Associations between HART CVE score and risk of MACE as a function of number of CTO vessels are detailed in **Supplemental Table 2**. This shows generally higher risk associated with more CTO vessels, particularly with higher HART CVE scores. Across each category of CTO extent, those with low HART CVE scores had similar HR across 1-, 2-, or 3-vessel CTO groups. These consistent results across 1-3 vessel CTO patients indicates robustness of the biomarker panel across a spectrum of CTO patients. Relevant to the CV death/HF hospitalization outcome the C-statistic of the model for predicting 4-year CV death/HF hospitalization was 0.84 (0.78, 0.90). **Table 5** displays the performance of HART CVE panel for CV death/HF hospitalization across time points. This shows, comparable to the performance of the HART CVE panel to predict triple MACE, graded risk across low-, medium- and high-risk scores was seen for CV death/HF hospitalization at each time point examined. For example, compared to the referent (the low-risk score group), the high-risk group had a hazard ratio of 26.1 (95% CI: 7.55, 90.2) at 1 year, 16.8 (95% CI: 6.11, 46.2) at 2 years and 15.6 (95% CI: 6.18, 39.2) at 4 years (all P value <0.001). In addition, the model’s calibration was excellent **(Table 6).** View this table: [Table 5:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/T5) Table 5: Performance of HART CVE Panel for CV death/HF hospitalization across study time points. View this table: [Table 6:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/T6) Table 6: Calibration for CV death/HF hospitalization. As depicted in **Figure 2 and 3** the time to first triple MACE or CV death/HF hospitalization was shortest for study participants with a CTO and a high-risk HART CVE classification. ![Figure 2:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/07/23/2023.07.19.23292911/F2.medium.gif) [Figure 2:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/F2) Figure 2: Cumulative event curves over a follow up period of 4 years in patients with ≥1 coronary chronic total occlusion (CTO) vessels categorized by HART CVE risk group and subsequent major adverse cardiovascular events (MACE) rates. Subjects in the high-risk HART CVE group had considerably higher event rates from enrollment to 4 years. ![Figure 3:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/07/23/2023.07.19.23292911/F3.medium.gif) [Figure 3:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/F3) Figure 3: Cumulative event curves over 4-year follow up in patients with coronary ≥1 CTO vessels categorized by HART CVE risk group and subsequent cardiovascular death or heart failure rates. Subjects in the high-risk HART CVE group had considerably higher event rates from enrollment to 4 years. ## Discussion Among CASABLANCA study patients with CTO lesion that was not bypassed with a patent distal bypass graft, a multimarker weighted panel comprised of four biomarker proteins (NT-proBNP, KIM-1, Osteopontin and TIMP-1) accurately risk stratified CTO patients into low-, medium- and high-risk groups across a very broad range of risk for both triple MACE as well as CV death/HF hospitalization. The HART CVE panel provided excellent discrimination for predicting such risk throughout the 4-year follow-up period. By 4 years, compared to a referent low-risk population, the high-risk group had a greater than 12-fold higher MACE risk during the 4 years of follow-up and nearly 16-fold higher risk for CV death/HF hospitalization during that same period. Even though patients with numerically more CTO vessels had higher risk for adverse outcome, even in this context the biomarker panel remained able to stratify risk for MACE outcomes. The ability to stratify baseline risk in patients with CTOs remains unexplored, so to our knowledge, this study is the first to describe the role of biomarker testing for this indication. The four biomarkers included in the HART CVE panel reflect various aspects of pathophysiology among patients with CTOs (**Central Illustration**). NT-proBNP, which is released due to LV wall stretch secondary to LV dysfunction20 and myocardial ischemia21, has also been associated with severity22, 23 and long-term prognosis of patients with stable CAD24–26. KIM-1 is associated with progressive renal disease27–29 but is also elevated in proportion to the presence and severity of CAD30. Osteopontin regulates myofibroblast differentiation and production of type I collagen production, is upregulated following myocardial infarction, and associates with cardiac fibrosis31. Lastly, TIMP-1 is involved in the degradation of extracellular matrix proteins. Increased expression of TIMP-1 occurs following chronic pressure overload in myocardium, is associated with cardiac fibrosis, and may be linked to coronary plaque instability32. While abundant reports are present regarding models to predict in-hospital/short-term outcomes following CTO PCI, few data exist regarding the use of pre-PCI variables for predicting longer-term clinical risk among individuals with CTO. The results of this study suggest that a validated biomarker panel can stratify risk accurately in individuals with coronary CTO, even among those with numerically more CTO vessels. Arguably, given the risk/benefit trade-off of CTO PCI, having a tool to judge risk for short, medium, and longer-term risk for MACE or HF events may inform personalized and intensified medication administration and follow-up frequency, and may similarly dictate a threshold for proceeding with CTO PCI. For example, among those with a low-risk HART CVE score, regardless of the number of CTO vessels, the MACE risk was low, which might suggest a continued medical therapy strategy, while in patients with similar number of CTO vessels, a higher risk score consistently predicted greater MACE events at 1, 2, and 4 years; such individuals, within the context of shared decision making, might be more reasonably considered for earlier attempt at CTO revascularization for improved prognosis, independent of symptom status. Another potential use of the HART CVE score could be to enrich clinical trials with CTO patients more likely to experience MACE. For example, patients with moderate or higher HART CVE scores could potentially be part of future randomized control trials investigating the benefits of CTO PCI on outcomes such as MACE and CV death/HF hospitalization providing utilities for sufficient powering of such studies. More precisely, given the event rates in those with the most elevated HART CVE results (60% at 4 years, compared to a typical 4-year event of 25% in a post-ACS population33), clinical trials evaluating CTO PCI for improved prognosis could enroll more efficiently if utilizing a pre-stratified population expected to have higher CV event rates based on an elevated HART CVE test. Whether PCI of a CTO as part of a revascularization strategy can reduce the elevated risk seen in those with a higher risk HART CVE panel result remains speculative, but this study—leveraging results from a novel biomarker panel—represents an important first step that creates further possibilities. Besides triple MACE, in this study we also chose to examine rates of incident CV death/HF hospitalization as an outcome measure, as HF symptoms are common among persons with CTOs34, 35 and successful CTO PCI is often associated with dyspnea improvement34. The high HF event rate in this study is of note as is the fact that a panel that leverages concentration of NT-proBNP was comparably discriminatory for HF events to 4 years from study enrolment. ### Study limitations Although the study was performed with a careful methodologic approach, limitations to our study exist. First, the CASABLANCA study participants were predominantly male and Caucasian with a smaller representation of patients with traditional risk factors for CAD such as smoking (12%) and diabetes mellitus (36%). Second, the number of patients from which we derived and validated our findings was relatively small. Third, we only measured biomarkers at a single point in time, which may not reflect levels at future time periods. The study results require further validation and testing in a randomized controlled study. Fourth, the effects of revascularization on MACE during follow-up were not adjusted; salutary effect of revascularization would be expected to undermine the results of the HART CVE test, which was not observed. Finally, whether aggressive treatment strategies such as CTO PCI in patients with high-risk score will modify their risk status and whether that will reflect on long-term outcomes remains unknown but is a testable hypothesis. In conclusion, a multi-biomarker panel developed using targeted proteomics and machine learning was highly accurate for the risk stratification of patients with CTOs. The panel was able to accurately predict both incident triple MACE as well as CV death/HF hospitalization over a 4-year period. The potential advantages of using a biomarker leveraged approach for decision-making in CTO patients include its use for guiding personalized medical therapy and surveillance, and to help select patients that might benefit prognostically from CTO PCI. ### Clinical Perspective * **Competency in medical knowledge:** Patients with a coronary chronic total occlusions (CTO) experience elevated MACE rates, but the role of CTO percutaneous coronary intervention (PCI) in reducing MACE is unclear and the procedures itself carries risk. A risk stratification tool for long-term risk CTO patients is therefore needed. * **Translational outlook 1:** A multi-biomarker panel from CASABLANCA study has previously shown predict MACE. * **Translational outlook 2:** The HART CVE panel was used to risk stratify CTO patients in to low-, medium- and high-risk groups. Using the low-risk group as reference, the high-risk group had considerably higher incidence of triple MACE, with a 60% incidence of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, as well as CV death/HF hospitalization at 4 years. * **Translational outlook 3:** Using this multi-biomarker panel, physicians may be able to risk stratify and select high-risk CTO patients for enhanced secondary CAD prevention and surveillance, and enrichment for CTO PCI randomized trials. ## Funding Dr. Mohebi is supported by the Barry Fellowship. Dr. McCarthy is supported by the NHLBI T32 postdoctoral training grant (5T32HL094301-12). Dr. Januzzi is supported by the Hutter Family Professorship. ## Disclosures **Dr. McCarthy** has received consulting income from Abbott Laboratories **Dr. Jaffer:** sponsored research: Canon, Siemens, Shockwave, Teleflex, Mercator, Boston Scientific, HeartFlow, Neovasc; consultant/speakers fees: Boston Scientific, Siemens, Magenta Medical, Philips, Biotronik, Mercator, Abiomed; Equity interest: Intravascular Imaging Inc, DurVena. Massachusetts General Hospital – licensing arrangements: Terumo, Canon, Spectrawave, for which FAJ has right to receive royalties. **Dr. Megarat and Ms. Rhyne** are employees of Prevencio. **Dr. Januzzi:** is a Trustee of the American College of Cardiology; is a board member of Imbria Pharmaceuticals; has received grant support from Abbott Diagnostics, Applied Therapeutics, HeartFlow, Innolife and Novartis; has received consulting income from Abbott Diagnostics, AstraZeneca, Beckman Coulter, Jana Care, Janssen, Novartis, Prevencio, Quidel, Roche Diagnostics; and participates in clinical endpoint committees/data safety monitoring boards for AbbVie, Abbott, Bayer, Siemens, Pfizer and Takeda. The rest of the authors have no disclosure. ## Data Availability All the data for the manuscript is available ![Central illustration:](http://medrxiv.org/http://medrxiv.stage.highwire.org/content/medrxiv/early/2023/07/23/2023.07.19.23292911/F4.medium.gif) [Central illustration:](http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292911/F4) Central illustration: Patients with ≥1 CTO vessel may experience a poorer prognosis stratified by a biomarker panel level (HART CVE) that includes kidney injury molecule-1, N-terminal pro-B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1. Mechanistically, this finding might reflect progression of higher risk plaques and/or myocardial demand ischemia/infarction, driving an increased risk of major adverse cardiovascular events. * Received July 19, 2023. * Revision received July 19, 2023. * Accepted July 23, 2023. * © 2023, Posted by Cold Spring Harbor Laboratory The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission. ## References 1. 1.Tsai TT, Stanislawski MA, Shunk KA, et al. Contemporary Incidence, Management, and Long-Term Outcomes of Percutaneous Coronary Interventions for Chronic Coronary Artery Total Occlusions: Insights from the VA CART Program. J Am Coll Cardiol Intv. 2017;10: 866–875. 2. 2.Stone GW, Kandzari DE, Mehran R et al. Percutaneous Recanalization of Chronically Occluded Coronary Arteries. A Consensus Document: Part I. Circulation. 2005; 112:2364–2372 [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjExOiIxMTIvMTUvMjM2NCI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA3LzIzLzIwMjMuMDcuMTkuMjMyOTI5MTEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 3. 3.Watanabe H, Morimoto T, Shiomi H, Kawaji T, Furukawa Y, Nakagawa Y. Chronic total occlusion in non-infarct-related artery is associated with increased short-and long-term mortality in patients with ST-segment elevation acute myocardial infarction complicated by cardiogenic shock (from the CREDO-Kyoto AMI registry). Catheter Cardiovasc Interv 2018; 92: 455–463 4. 4.Vallabhajosyula S., Prasad A., Gulati R., Barsness G.W. Contemporary prevalence, trends, and outcomes of coronary chronic total occlusions in acute myocardial infarction with cardiogenic shock. Int J Cardiol Heart Vasc. 2019; 24:100414. 5. 5.Claessen BE, Dangas GD, Weisz G et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J. 2012;33:768–75. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurheartj/ehr471&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=22240495&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000287804500002&link_type=ISI) 6. 6.Sapontis J, Salisbury AC, Yeh RW et al. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv. 2017; 10:1523–1534. [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiamludCI7czo1OiJyZXNpZCI7czoxMDoiMTAvMTUvMTUyMyI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA3LzIzLzIwMjMuMDcuMTkuMjMyOTI5MTEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 7. 7.Kandzari DE, Karmpaliotis D, Kini AS et al. Late-term safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: Final 4-year results from the evaluation of the XIENCE coronary stent, Performance, and Technique in Chronic Total Occlusions (EXPERT CTO) multicenter trial. Catheter Cardiovasc Interv. 2019; 94:509–515. 8. 8.Valenti R, Migliorini A, De Gregorio MG et al. Impact of complete percutaneous revascularization in elderly patients with chronic total occlusion. Catheter Cardiovasc Interv. 2020; 95:145–153. 9. 9.George S, Cockburn J, Clayton TC et al. British Cardiovascular Intervention Society; National Institute for Cardiovascular Outcomes Research. Long-term follow-up of elective chronic total coronary occlusion angioplasty: analysis from the U.K. Central Cardiac Audit Database. J Am Coll Cardiol. 2014; 64:235–243. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjg6IjY0LzMvMjM1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDcvMjMvMjAyMy4wNy4xOS4yMzI5MjkxMS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 10. 10.Henriques JP, Hoebers LP, Råmunddal T, et al. Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial. J Am Coll Cardiol. 2016; 68:1622–1632. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjEwOiI2OC8xNS8xNjIyIjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDcvMjMvMjAyMy4wNy4xOS4yMzI5MjkxMS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 11. 11.Obedinskiy AA, Kretov EI, Boukhris M, et al. The IMPACTOR-CTO Trial. JACC Cardiovasc Interv. 2018;11:1309–1311. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiRlVMTCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiamludCI7czo1OiJyZXNpZCI7czoxMDoiMTEvMTMvMTMwOSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA3LzIzLzIwMjMuMDcuMTkuMjMyOTI5MTEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 12. 12.Werner GS, Martin-Yuste V, Hidlick-Smith D et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions, European Heart Journal, 2018; 39: 2484–2493. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/eurheartj/ehy220&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=29722796&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) 13. 13.Mashayekhi K, Nührenberg TG, Toma A et al. A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion: The REVASC Trial. J Am Coll Cardiol Intv. 2018;11:1982–1991 14. 14.Lee SW, Lee PH, Ahn JM et al. Randomized Trial Evaluating Percutaneous Coronary Intervention for the Treatment of Chronic Total Occlusion. The DECISION-CTO Trial. Circulation. 2019;139:1674–1683 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/CIRCULATIONAHA.118.031313&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=30813758&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) 15. 15.Juricic SA, Tesic MB, Galassi AR et al. Randomized Controlled Comparison of Optimal Medical Therapy with Percutaneous Recanalization of Chronic Total Occlusion (COMET-CTO). Int Heart J. 2021;62:16–22. 16. 16.Hirai T, Nicholson WJ, Sapontis J et al. A Detailed Analysis of Perforations During Chronic Total Occlusion Angioplasty. JACC Cardiovasc Interv. 2019;12:1902–1912. [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiamludCI7czo1OiJyZXNpZCI7czoxMDoiMTIvMTkvMTkwMiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA3LzIzLzIwMjMuMDcuMTkuMjMyOTI5MTEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 17. 17.Gaggin HK, Bharadwaj A, Belcher A et al. Design, methods, baseline characteristics and interim results of the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. IJC Metabolic & Endocrine 2014; 5:11–18 18. 18.Fefer P, Knudtson ML, Cheema AN et al. Current perspectives on coronary chronic total occlusions: the Canadian Multicenter Chronic Total Occlusions Registry. J Am Coll Cardiol. 2012; 59:991–997. [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjk6IjU5LzExLzk5MSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA3LzIzLzIwMjMuMDcuMTkuMjMyOTI5MTEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 19. 19.McCarthy CP, van Kimmenade RRJ, Gaggin HK et al. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study). Am J Cardiol. 2017; 120:25–32 20. 20.Nakagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy: evidence for brain natriuretic peptide as an ‘emergency’ cardiac hormone against ventricular overload. J Clin Invest 1995; 96:1280–1287. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1172/JCI118162&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=7657802&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=A1995RR85300015&link_type=ISI) 21. 21.Goetze JP, Christoffersen C, Perko M et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17:1105–1107. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1096/fj.02-0796fje&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=12709407&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) 22. 22.Weber M, Dill T, Arnold R et al: N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004; 148:612–620. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.ahj.2004.04.021&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15459591&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000224650900012&link_type=ISI) 23. 23.Ndrepepa G, Braun S, Mehilli J et al: Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 2005; 95:553–557. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.amjcard.2004.10.034&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15721090&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000227156400001&link_type=ISI) 24. 24.Kragelund C, Grønning B, Køber L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005; 352:666–675. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa042330&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=15716560&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000227031100005&link_type=ISI) 25. 25.Ndrepepa G, Braun S, Niemöller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation. 2005; 112:2102–2107. [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjExOiIxMTIvMTQvMjEwMiI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA3LzIzLzIwMjMuMDcuMTkuMjMyOTI5MTEuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 26. 26.Omland T, Sabatine MS, Jablonski KA, et al ; PEACE Investigators. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007; 50:205–214 [FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJhY2NqIjtzOjU6InJlc2lkIjtzOjg6IjUwLzMvMjA1IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDcvMjMvMjAyMy4wNy4xOS4yMzI5MjkxMS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 27. 27.Geng J, Qiu Y, Qin Z, Su B. The value of kidney injury molecule 1 in predicting acute kidney injury in adult patients: a systematic review and Bayesian meta-analysis. J Transl Med. 2021; 19:105. 28. 28.Lupu L, Abukatash H, Banai A et al: Relation of baseline neutrophil gelatinase-associated lipocalin (NGAL) levels and contrast-induced nephropathy following percutaneous coronary intervention among chronic kidney disease patients. J Clin Med. 2021;10:5403. 29. 29.Ibrahim NE, McCarthy CP, Shrestha S et al. Blood kidney injury molecule-1 predicts short- and longer-term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography-Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. Am. Heart J. 2019;209: 36–46 30. 30.McCarthy CP, Neumann JT, Michelhaugh SA et al Derivation and External Validation of a High-Sensitivity Cardiac Troponin-Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease. J Am Heart Assoc 2020;9: e017221. 31. 31.Singh M, Foster CR, Dalal S. et al: Osteopontin: role in extracellular matrix deposition and myocardial remodeling post-MI. J. Mol. Cell. Cardiol. 2010; 48:538–543 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.yjmcc.2009.06.015&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=19573532&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom) [Web of Science](http://medrxiv.org/lookup/external-ref?access_num=000274922300017&link_type=ISI) 32. 32.Heymans S, Schroen B, Vermeersch P et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation. 2005; 112:1136–44. [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6MTQ6ImNpcmN1bGF0aW9uYWhhIjtzOjU6InJlc2lkIjtzOjEwOiIxMTIvOC8xMTM2IjtzOjQ6ImF0b20iO3M6NTA6Ii9tZWRyeGl2L2Vhcmx5LzIwMjMvMDcvMjMvMjAyMy4wNy4xOS4yMzI5MjkxMS5hdG9tIjt9czo4OiJmcmFnbWVudCI7czowOiIiO30=) 33. 33.Qintar M, Grantham JA, Sapontis J, et al. Dyspnea Among Patients with Chronic Total Occlusions Undergoing Percutaneous Coronary Intervention: Prevalence and Predictors of Improvement. Circ Cardiovasc Qual Outcomes. 2017;10: e003665. [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6ODoiY2lyY2N2b3EiO3M6NToicmVzaWQiO3M6MTM6IjEwLzEyL2UwMDM2NjUiO3M6NDoiYXRvbSI7czo1MDoiL21lZHJ4aXYvZWFybHkvMjAyMy8wNy8yMy8yMDIzLjA3LjE5LjIzMjkyOTExLmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 34. 34.Steen DL, Khan I, Andrade K, Koumas A, Giugliano RP. Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post-Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States. Journal of the American Heart Association 2022;11: e022198 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1161/JAHA.121.022198&link_type=DOI) 35. 35.Safley DM, Grantham JA, Hatch J et al. Quality of life benefits of percutaneous coronary intervention for chronic occlusions. Catheter Cardiovasc Interv. 2014; 84:629–634. [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1002/ccd.25303&link_type=DOI) [PubMed](http://medrxiv.org/lookup/external-ref?access_num=24259445&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F07%2F23%2F2023.07.19.23292911.atom)